Total for the last 12 months
number of access : ?
number of downloads : ?
ID 119400
Author
Ikeda-Imafuku, Mayumi Wakayama Medical University|Tokushima University
Fukuta, Tatsuya Wakayama Medical University KAKEN Search Researchers
Chuang, Victor Tuan Giam Curtin University
Sawa, Tomohiro Kumamoto University
Maruyama, Toru Kumamoto University
Otagiri, Masaki Sojo University
Ishima, Yu Tokushima University|Kyoto Pharmaceutical University Tokushima University Educator and Researcher Directory
Keywords
supersulfides
serum albumin
acute kidney injury
oxidative stress
reactive oxygen species
Content Type
Journal Article
Description
Oxidative stress is responsible for the onset and progression of various kinds of diseases including rhabdomyolysis-induced acute kidney injury (AKI). Antioxidants are, therefore, thought to aid in the recovery of illnesses linked to oxidative stress. Supersulfide species have been shown to have substantial antioxidative activity; however, due to their limited bioavailability, few supersulfide donors have had their actions evaluated in vivo. In this study, human serum albumin (HSA) and N-acetyl-L-cysteine polysulfides (NACSn), which have polysulfides in an oxidized form, were conjugated to create a supersulfide donor. HSA is chosen to be a carrier of NACSn because of its extended blood circulation and high level of biocompatibility. In contrast to a supersulfide donor containing reduced polysulfide in HSA, the NACSn-conjugated HSAs exhibited stronger antioxidant activity than HSA and free NACSn without being uptaken by the cells in vitro. The supersulfide donor reduced the levels of blood urea nitrogen and serum creatinine significantly in a mouse model of rhabdomyolysis-induced AKI. Supersulfide donors significantly reduced the expression of oxidative stress markers in the kidney. These results indicate that the developed supersulfide donor has the therapeutic effect on rhabdomyolysis-induced AKI.
Journal Title
Pharmaceuticals
ISSN
14248247
Publisher
MDPI
Volume
17
Issue
1
Start Page
128
Published Date
2024-01-18
Rights
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Pharmaceutical Sciences